Skip to content

Efficacy and safety of regulating intestinal flora with yiqi-yangxue and tongluo prescriptions in improving left ventricular remodeling and cardiac function in patients with acute coronary syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial

Efficacy and safety of regulating intestinal flora with yiqi-yangxue and tongluo prescriptions in improving left ventricular remodeling and cardiac function in patients with acute coronary syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048457
Enrollment
Unknown
Registered
2021-07-09
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute coronary syndrome

Interventions

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 74 Years

Inclusion criteria

Inclusion criteria: 1. Outpatient or inpatient patients aged 18-74 (including 18 and 74) years; 2. Meet the Western Medicine diagnostic criteria of ''Guidelines for Rapid Diagnosis and Treatment of Acute Coronary Syndrome (2019)'', the primary disease is acute coronary syndrome, and the condition is relatively stable; 3. Serum NT-proBNP level increased, aged 18-50 years, NT-proBNP>450ng/L; aged 51-74 years, NT-proBNP>900ng/L; 4. Patients who have no allergic reaction to the drugs used in this treatment; 5. Patients who are willing to sign the informed consent form and cooperate with the treatment.

Exclusion criteria

Exclusion criteria: 1. Patients with severe mental disorders; 2. Patients with other heart diseases; 3. Patients who are pregnant or breastfeeding; 4. Patients with liver and kidney damage; 5. Patients with cerebral hemorrhage, gastrointestinal bleeding and other diseases; 6. Patients who are unwilling to cooperate with treatment.

Design outcomes

Primary

MeasureTime frame
N-terminal pro-B type natriuretic peptide;

Secondary

MeasureTime frame
Tissue Doppler measurements E’;Tissue Doppler measurement E/e’;Number of angina attacks;Frequency of angina attacks;The duration of the angina attack;

Countries

China

Contacts

Public ContactBu Peili

Qilu Hospital of Shandong University

bupeili@medmail.com.cn+86 18560086596

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026